Advertisement
Singapore markets close in 4 hours 51 minutes

  • Straits Times Index

    3,270.65
    -29.39 (-0.89%)
     

  • Nikkei

    38,283.66
    -551.44 (-1.42%)
     

  • Hang Seng

    18,437.06
    -42.31 (-0.23%)
     

  • FTSE 100

    8,313.67
    +100.18 (+1.22%)
     

  • Bitcoin USD

    62,920.32
    -294.99 (-0.47%)
     

  • CMC Crypto 200

    1,303.53
    -61.59 (-4.51%)
     

  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     

  • Dow

    38,884.26
    +31.99 (+0.08%)
     

  • Nasdaq

    16,332.56
    -16.69 (-0.10%)
     

  • Gold

    2,324.50
    +0.30 (+0.01%)
     

  • Crude Oil

    78.10
    -0.28 (-0.36%)
     

  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     

  • FTSE Bursa Malaysia

    1,605.97
    +0.29 (+0.02%)
     

  • Jakarta Composite Index

    7,085.86
    -37.75 (-0.53%)
     

  • PSE Index

    6,595.97
    -22.61 (-0.34%)
     

FDA clears Biogen Idec's hemophilia A drug

FDA approves Biogen Idec's Eloctate, a hemophilia treatment that lasts longer than older drugs

Associated Press

NEW YORK (AP) -- U.S. regulators on Friday approved Biogen Idec's drug Eloctate, a hemophilia A treatment that is designed to last longer than older drugs.

The Food and Drug Administration approved Eloctate for use in adults and children.

Hemophilia A is a rare, inherited disease that affects blood clotting.

Biogen Idec said that patients have to take older drugs every other day or three days a week, while Eloctate needs to be infused every three to five days. Infused drugs are taken through a needle or catheter.

The Cambridge, Massachusetts, company said that around 16,000 people in the U.S. have hemophilia A.

Shares of Biogen Idec Inc. rose $3.15, or 1 percent, to $320.70 in aftermarket trading. The stock had shed $2.58 to close at $317.55 on Friday.